SCHEMBL2913199

SCHEMBL2913199

Clc1ccccc1Nc1c(-c2ccccc2)nc2cnccn12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.70
GAA P10253 14/20 0.63
KDM4E B2RXH2 8/20 0.63
MAPK1 P28482 3/20 0.63
LMNA P02545 3/20 0.63
MAPT P10636 8/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
TP53 P04637 5/20 0.54
CDK9 P50750 1/20 0.54
TUBB4A P04350 2/20 0.52
TUBB P07437 2/20 0.52
TUBA3C P0DPH7 2/20 0.52
TUBA1B P68363 2/20 0.52
TUBA4A P68366 2/20 0.52
TUBB4B P68371 2/20 0.52
TUBB3 Q13509 2/20 0.52
TUBB2A Q13885 2/20 0.52
TUBB8 Q3ZCM7 2/20 0.52
TUBA3E Q6PEY2 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14484070 0.83 GAA (0.61) BRAFGAAKDM4EMAPK1LMNA
SCHEMBL2923400 0.83 GAA (0.83) BRAFGAAKDM4EMAPK1LMNA
SCHEMBL2913681 0.82 BRAF (1.00) BRAFGAAKDM4EMAPK1LMNA
SCHEMBL2921674 0.82 BRAF (0.77) BRAFGAAKDM4EMAPK1LMNA
SCHEMBL2924324 0.80 BRAF (0.91) BRAFGAAKDM4EMAPK1LMNA
SCHEMBL2921758 0.80 BRAF (0.77) BRAFGAAKDM4EMAPK1LMNA
SCHEMBL2918905 0.79 GAA (0.65) BRAFGAAKDM4EMAPK1LMNA
SCHEMBL2924128 0.78 GAA (0.78) BRAFGAAKDM4EMAPK1LMNA
SCHEMBL7963701 0.78 GAA (0.71) BRAFGAAKDM4EMAPK1LMNA
SCHEMBL12781599 0.75 ADRA1B (0.71) BRAFGAAKDM4EMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1901748-B1 ANGIOGENESIS INHIBITORS ONCALIS AG (CH) 2010-09-08 EP disclosed
EP-1901748-B1 ANGIOGENESIS INHIBITORS ONCALIS AG (CH) 2010-09-08 EP disclosed
EP-1765351-B9 PROTEIN KINASE INHIBITORS ONCALIS AG (CH) 2010-03-24 EP disclosed
EP-1765351-B9 PROTEIN KINASE INHIBITORS ONCALIS AG (CH) 2010-03-24 EP disclosed
EP-1765351-B1 PROTEIN KINASE INHIBITORS ONCALIS AG (CH) 2009-03-04 EP disclosed
EP-1765351-B1 PROTEIN KINASE INHIBITORS ONCALIS AG (CH) 2009-03-04 EP disclosed
US-20070149535-A1 Protein kinase inhibitors ONCALIS AG (CH) 2007-06-28 US disclosed
US-20070149535-A1 Protein kinase inhibitors ONCALIS AG (CH) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149535-A1 Protein kinase inhibitors FLT1, ERBB2, ERBB3 BRAF 42/4885GAA 3677/4885KDM4E 1064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.